Daniel Park

Teclistamab Monotherapy in Relapsed or Refractory Multiple Myeloma: A Real-World Focused Systematic Review and Meta-Analysis of Efficacy and Safety

Background/Objectives: Teclistamab is a B-cell maturation antigen (BCMA)-directed bispecific antibody approved for relapsed or refractory multiple myeloma (RRMM). Although prior analyses have summarized teclistamab outcomes, some have included combination regimens or broader comp...